Clinical trials: Pituitary Cancer
Pituitary Adenoma, Surgery
Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas
We hypothesize that the effects of non-steroidal anti-inflammatory drugs (NSAIDS) for pain relief among patients with pituitary adenomas undergoing transnasal transsphenoidal surgeries are non-inferior to tramadol.
- Conditions
- Pituitary Adenoma, Surgery, Pain
- Trial name
- NCT04611685
- Testing
- NSAID, Tramadol
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Peking Union Medical College Hospital
Brain Tumor, Primary, Meningioma
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination…
- Conditions
- Brain Tumor, Primary, Meningioma, Schwannoma, Pituitary Adenoma
- Trial name
- SOLOMON (NCT05254197)
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
Hypothalamic Neoplasms, Pituitary Diseases
The Cardiovascular Changes Associated With Septal Local Anaesthesia
The purpose of this study is to determine the effects on the heart of injecting local anaesthetic into the nose prior to surgery on the pituitary gland?
- Conditions
- Hypothalamic Neoplasms, Pituitary Diseases, Anesthesia, Local
- Trial name
- NCT03137615
- Testing
- Pituitary surgery, local anaesthetic injection
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Acromegaly, Neuroendocrine Tumours
Somatuline Predictive Factors in Acromegaly and NET
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
- Trial name
- SOPRANo (NCT01840449)
- Testing
- Somatuline Autogel® 60, 90 or 120 mg
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Ipsen
CNS Tumors, Meningioma
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma…
- Conditions
- CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma
- Trial name
- DOMINO-START (NCT04081701)
- Testing
- Ga68-DOTATATE-PET/MRI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Myoma
Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy
In this study, the investigators will investigate the effectiveness of a topical tranexamic acid plus perivascular vasopressin compared with perivascular vasopressin alone for the reduction of blood loss at the time of myomectomy
- Trial name
- NCT03880045
- Testing
- Topical TA, vasopressin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Aswan University Hospital
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pituitary Tumors
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate…
- Trial name
- NCT01689727
- Testing
- Technetium Tc 99m EC20
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Endocyte
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Dementia, Movement Disorders
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner.
- Conditions
- Dementia, Movement Disorders, ALS - Amyotrophic Lateral Sclerosis, Epilepsy
- Trial name
- NCT07595666
- Testing
- Standard-of-care PET/CT, NeuroEXPLORER
- Where
- Belgium
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Pituitary Adenoma, Pituitary Neuroendocrine Tumor
Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors
The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors.
- Trial name
- NCT06679816
- Testing
- Hormone replacement therapy
- Where
- China
- Volunteers
- 882 people
- Sponsor
- Beijing Tiantan Hospital
Pleuropulmonary Blastoma, Cystic Nephroma
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB are not defined.
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma
- Trial name
- PPB (NCT00565903)
- Where
- United States
- Volunteers
- 1,247 people, healthy volunteers welcome
- Sponsor
- Ashley Hill
Craniopharyngioma, Growth Hormone Deficiency (GHD)
Hypothalamic-Stratified Nursing Pathway for Pediatric Craniopharyngioma
The goal of this multicenter retrospective cohort study is to determine whether MRI-graded hypothalamic injury severity predicts growth-hormone deficiency (GHD) and neuropsychological morbidity in 500 children and adolescents (≤…
- Trial name
- NCT07342686
- Where
- China
- Volunteers
- 500 people
- Sponsor
- West China Hospital
Nelson Syndrome
Pasireotide Therapy in Patients With Nelson's Syndrome
Nelson's syndrome, an expanding pituitary tumour, occurs in up to 30% of adults after bilateral adrenalectomy for Cushing's disease, for which no medical treatment exists.
- Trial name
- NCT01617733
- Testing
- Pasireotide
- Where
- 4 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Pituitary Adenoma, Visual Impairment
Clinical Study of Structural and Functional Evaluation of the Visual Pathway
Sellar area tumors such as pituitary adenoma, craniopharyngioma and meningioma, etc, commonly lead to visual impairment symptoms.
- Conditions
- Pituitary Adenoma, Visual Impairment, Sellar Tumor, Neuroimaging
- Trial name
- NCT03591315
- Testing
- resting state fMRI, visual tasking state fMRI, diffusion tensor imaging
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Non-Functional Pituitary Adenoma
Physical Attendance Versus Telephone or Video Follow-up in Patients With Non-functioning Pituitary Tumors.
The primary purpose of this study is to compare the safety of routine telephone assessment versus in-person assessment during a two-year period for patients with non-functioning pituitary adenomas.
- Trial name
- PITCARE (NCT06297473)
- Testing
- Telephone-/video follow-up, In-person follow-up
- Where
- Denmark
- Volunteers
- 812 people
- Sponsor
- Zealand University Hospital
Prolactin-Producing Pituitary Tumor
A Study of Pasireotide in People With Prolactinoma
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy.
- Trial name
- NCT06295952
- Testing
- Pasireotide, SF-36 and HADS
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pituitary Adenoma, Prolactinoma
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
The aim of this study is to investigate whether inhibition of serum prolactin levels below normal range during cabergoline administration may reduce the recurrence rate after drug withdrawal in patients with prolactinomas.
- Conditions
- Pituitary Adenoma, Prolactinoma, Pituitary Tumor, Recurrence Tumor
- Trial name
- NCT03457389
- Testing
- Cabergoline
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Acromegaly
A Prospective Study of Outcome After Therapy for Acromegaly
The purpose of this study is to evaluate hormone values and other markers of disease activity in a cohort of patients with acromegaly at the time of diagnosis and then prospectively after surgical or other treatment.
- Trial name
- NCT01809808
- Testing
- Surgery for acromegaly, Medications for acromegaly, Total body magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Columbia University
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.